Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

Zenopa are always helpful and professional and always returned my calls in a timely manner. I always find that the positions are tailored correctly and there is no time wasted in applying for unsuitab...
Alison, 2014

Boehringer Ingelheim and Ablynx extend nanobody alliance

22 March 2012 00:00 in Pharmaceutical Company Product News

Boehringer Ingelheim has extended its global strategic nanobody alliance with life science company Ablynx by two years.

The global strategic alliance to discover, develop and commercialise up to ten different nanobody therapeutics is now set to run until September 2014 and will see Ablynx provided with an additional 6.6 million euros (5.5 million pounds) in funding.

Following this new agreement, all ten of the nanobody projects will be able to be advanced to a stage where Boehringer Ingelheim can potentially progress each of them into development.

Currently, two Nanobody programmes are undergoing preclinical trials and eight are at various stages of development across multiple disease areas, while one additional treatment for Alzheimer's disease has also been created under a separate scheme.

Dr Edwin Moses, chief executive officer and chairman of Ablynx, said: "We are very pleased to have eleven nanobody programmes potentially able to make an important contribution to Boehringer Ingelheim's research and development pipeline."

Last month, it was announced that the company will also be allying with Xencor to create new biosuperior monoclonal antibodies, based on the protein design automation platform technology Xtend.ADNFCR-8000103-ID-801323819-ADNFCR

Other news stories from 22/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd